Aspen Neuroscience, Inc. (ASPE)
Data as of , from SEC Form 4 filings.
See up to 3 months of ASPE. The 7-day demo opens the 1M and 3M ranges and puts ASPE on your watchlist.
Start 7-day demoLatest ASPE insider trades
About Aspen Neuroscience, Inc. (ASPE)
Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson's disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells.
- 2026
- Nasdaq
https://www.aspenneuroscience.comSEC filings for ASPE on EDGAR
ASPE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 4 | 2,533,333 | $38.00M |
| Other acquisition / disposition | 28 | 5,416,706 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ASPE insider transactions (Form 4)
324 Form 4 filings on record, the earliest from Nov 3, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. - 10% Owner | Open-market purchase | Common Stock | 66,666 | $15.00 | $1.00M | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Common Stock | 187,182 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Common Stock | 298,258 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Common Stock | 286,304 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Common Stock | 295,490 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Common Stock | 259,948 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Open-market purchase | Common Stock | 66,667 | $15.00 | $1.00M | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Common Stock | 298,258 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Common Stock | 286,304 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Common Stock | 295,490 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Common Stock | 214,355 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Open-market purchase | Common Stock | 1,200,000 | $15.00 | $18.00M | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Series Seed Convertible Preferred Stock | 187,182 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Series A-1 Convertible Preferred Stock | 298,258 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Series A-1 Convertible Preferred Stock | 298,258 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Series A-2 Convertible Preferred Stock | 286,304 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Series A-2 Convertible Preferred Stock | 286,304 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Series B Convertible Preferred Stock | 295,490 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Series B Convertible Preferred Stock | 295,490 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Series C Convertible Preferred Stock | 259,948 | - footnote F3 | - | |
| ARCH Venture Fund X, L.P. - 10% Owner | Other | Series C Convertible Preferred Stock | 214,355 | - footnote F3 | - | |
| ||||||
| ARCH Venture Partners XIV, L.P. - 10% Owner | Open-market purchase | Common Stock | 1,200,000 | $15.00 | $18.00M | |
| Andrew Spaventa - Director | Other | Common Stock | 70,194 | - footnote F1 | - | |
| Andrew Spaventa - Director | Other | Common Stock | 180,221 | - footnote F1 | - | |
| Andrew Spaventa - Director | Other | Series Seed Convertible Preferred Stock | 70,194 | - footnote F1 | - | |
| Andrew Spaventa - Director | Other | Series C Convertible Preferred Stock | 180,221 | - footnote F1 | - | |
| ||||||
| Faheem Hasnain - Officer | Other | Common Stock | 14,913 | - footnote F1 | - | |
| Faheem Hasnain - Officer | Other | Common Stock | 14,316 | - footnote F1 | - | |
| Faheem Hasnain - Officer | Other | Common Stock | 7,120 | - footnote F1 | - | |
| Faheem Hasnain - Officer | Other | Series A-1 Convertible Preferred Stock | 14,913 | - footnote F1 | - | |
| Faheem Hasnain - Officer | Other | Series A-2 Convertible Preferred Stock | 14,316 | - footnote F1 | - | |
| Faheem Hasnain - Officer | Other | Series C Convertible Preferred Stock | 7,120 | - footnote F1 | - | |
| ||||||
ASPE insider trading FAQ
What is the latest insider trade for ASPE?
Aspen Neuroscience, Inc. (ASPE) had 4 insider filings in the last 90 days, with the most recent on 3 November 2026. The full record for ASPE runs to 4 Form 4 filings, the earliest from 3 November 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ASPE stock?
4 insider purchases of ASPE were filed in the last 90 days, totaling $38.00M.
How many insiders are selling ASPE stock?
No insider sales of ASPE were filed in the last 90 days.
Where can I see ASPE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ASPE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
4The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - ARCH Venture Fund X, L.P. view on EDGAR
- - ARCH Venture Partners XIV, L.P. view on EDGAR
- - Andrew Spaventa view on EDGAR
- - Faheem Hasnain view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where ASPE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ASPE with a 7-day demo
- ASPE on your watchlist
- Every ASPE Form 4 filing on record
- Up to 3 months of ASPE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
